| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V39967-1mg |
≥99% | ￥510.00 |
货期：3-5天 | - | - | - | - |
|
V39967-5mg |
≥99% | ￥1230.00 |
货期：3-5天 | - | - | - | - |
|
V39967-10mg |
≥99% | ￥1980.00 |
货期：3-5天 | - | - | - | - |
|
V39967-25mg |
≥99% | ￥3710.00 |
货期：3-5天 | - | - | - | - |
|
V39967-50mg |
≥99% | ￥5320.00 |
货期：3-5天 | - | - | - | - |
|
V39967-100mg |
≥99% | ￥7280.00 |
货期：3-5天 | - | - | - | - |
|
V39967-200mg |
≥99% | ￥9790.00 |
货期：3-5天 | - | - | - | - |
|
| 参考文献： | 1. Hirose K, et al. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial. Radiother Oncol. 2021 Feb;155:182-187. 2. Hirose K, et al. Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan (10B)(SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck[J]. Annals of Oncology, 2019, 30: v460.3. Sato M, et al. Safety of Boron Neutron Capture Therapy with Borofalan (10B) and Its Efficacy on Recurrent Head and Neck Cancer: Real-World Outcomes from Nationwide Post-Marketing Surveillance[J]. Cancers, 2024, 16(5): 869. |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京